TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18082484
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment after fibrinolysis
Study: 14966633
Drug: Doxycycline slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline slow-release gel
Study: 11113239
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g Cr/day for 4 weeks
Study: 8232134
Drug: Flurbiprofen mouth
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen mouth wash 10 ml, 3 times daily for 7 days
Study: 8232134
Drug: Placebo mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouth wash 10 ml, 3 times daily for 7 days
Study: 25415695
Drug: 100 kV
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 kV with 90 mL iopromide 370 mg I/mL at 3.5 mL/s
Study: 23017784
Drug: Cola (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cola (1 liter daily)
Study: 23017784
Drug: Deionized water
Normalized name: WATER,DEIONIZED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deionized water (1 liter daily)
Study: 20415698
Drug: Bosentan (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (250 mg)
Study: 9931532
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (1 mg/m2/d)
Study: 7772643
Drug: Metyrapone 750
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metyrapone 750 mg followed by oCRF 0.3 microgram/kg
Study: 1969869
Drug: Procaterol 25
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol 25 micrograms escalating to 100 micrograms, and 100 micrograms twice daily
Study: 1969869
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of procaterol
Study: 375050
Drug: Alice/R‐75 2-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alice/R‐75 2-dose vaccine
Study: 375050
Drug: Alice/R‐75 1-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alice/R‐75 1-dose vaccine
Study: 375050
Drug: Placebo 2-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2-dose
Study: 375050
Drug: Alice strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alice strain monovalent influenza A vaccine
Study: 375050
Drug: R‐75 strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐75 strain monovalent vaccine
Study: 19387173
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin infusion (target glucose 100-150 mg/dl)
Study: 19387173
Drug: Standard intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intermittent insulin bolus (treat glucose > 150 mg/dl)
Study: 19387173
Drug: Standard intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intermittent insulin bolus
Study: 11128858
Drug: GAKIC (glycine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAKIC (glycine and L-arginine salt of alpha-ketoisocaproic acid calcium)
Study: 1487885
Drug: Nitrogranulong 5.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogranulong 5.2 mg
Study: 1487885
Drug: Nitrogranulong 10.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogranulong 10.4 mg
Study: 1487885
Drug: Trinitrolong 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trinitrolong 2 mg
Study: 1487885
Drug: Nitrong 6.5
Normalized name: Nitrong 6.5 MG Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrong 6.5 mg
Study: 25623589
Drug: Antibiotic (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic (oral sultamicillin) for five days
Study: 16621446
Drug: Acetyl-L-carnitine administration
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine administration
Study: 15641866
Drug: No antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antidepressant medication (control group)
Study: 15641866
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg mirtazapine (for treatment after diagnosis)
Study: 9573545
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion (30 g)
Study: 9573545
Drug: Control infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control infusion (30 g branched chain amino acids)
Study: 3400679
Drug: Cefoperazone 2
Normalized name: cefoperazone 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone 2 g intravenously every 12 hours and mezlocillin 4 g intravenously every six hours
Study: 3400679
Drug: Imipenem/cilastatin 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin 500 mg intravenously over 30 to 60 minutes every six hours
Study: 27544829
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy for insomnia (CBTi)
Study: 29499675
Drug: internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-delivered cognitive behavioural therapy (iCBT) for 8 weeks duration with regular post-session feedback by Psychological Wellbeing Practitioners
Study: 25697860
Drug: CET plus
Normalized name: Cocet Plus
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CET plus D-cycloserine (50 mg)
Study: 19655818
Drug: Cardioselective beta-adrenoceptor
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioselective beta-adrenoceptor antagonists (CSB); 212 patients (51% of 412 evaluable patients) were taking CSB.
Study: 16754416
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atomoxetine QD
Study: 16754416
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg atomoxetine BID
Study: 16754416
Drug: Both QD
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both QD and BID treatments
Study: 15317833
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg fenofibrate
Study: 26286133
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL 4.2% sodium bicarbonate
Study: 26286133
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 4.2% sodium bicarbonate
Study: 26286133
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL 2.1% sodium bicarbonate
Study: 23447103
Drug: Peaceful Mind
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peaceful Mind cognitive-behavioral therapy for anxiety in persons with dementia; details on dosage and duration not specified.
Study: 11601037
Drug: Sevoflurane in
Normalized name: sevoflurane Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane in oxygen without any other drugs (Control Group)
Study: 7776391
Drug: syrup with
Normalized name: Sambucus Elderberry Nighttime Syrup with Melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: syrup with a 10-ml measuring cup
Study: 7776391
Drug: syrup with
Normalized name: Sambucus Elderberry Nighttime Syrup with Melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: syrup with a 5-ml measuring spoon
Study: 7776391
Drug: tablets
Normalized name: Mesna Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: 7776391
Drug: single-dose sachets
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose sachets of antibiotic powder
Study: 2098143
Drug: Cefotaxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1 g intravenous infusion one hour before operation)
Study: 2098143
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g intravenous infusion one hour before operation)
Study: 2098143
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without antibiotics)
Study: 6253099
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) alone: 4500 rads in 5-6 weeks to primary tumor and regional lymph nodes, and 3500 rads in 2 1/2 weeks to brain as prophylaxis.
Study: 6253099
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) + chemotherapy (CT) with cyclophosphamide (500 mg/m2), Adriamycin (50 mg/m2), and DTIC (250 mg/m2) every 3 weeks for two cycles before RT and seven cycles post-RT.
Study: 30429927
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg IV ketamine
Study: 23864538
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg purified (-)-epicatechin perfused into an isolated jejunal segment
Study: 20299396
Drug: Weekly sunbed
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly sunbed use
Study: 19127801
Drug: Cefper injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefper injection (1.5 g cefoperazone and sulbactam)
Study: 19127801
Drug: Sulperazon injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulperazon injection (1.5 g cefoperazone and sulbactam)
Study: 15889524
Drug: Shenmai Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai Injection plus routine treatment
Study: 10498560
Drug: Azithromycin (1.0-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1.0-g dose)
Study: 8556221
Drug: Diarex Lactab
Normalized name: Diaprex
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diarex Lactab (test preparation)
Study: 8556221
Drug: Imodium capsules
Normalized name: loperamide Oral Capsule [Imodium]
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imodium capsules (reference preparation)
Study: 6109585
Drug: Bevantolol 75
Normalized name: bevantolol
DrugBank: Bevantolol (DB01295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevantolol 75 mg
Study: 6109585
Drug: Bevantolol 150
Normalized name: bevantolol
DrugBank: Bevantolol (DB01295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevantolol 150 mg
Study: 24989721
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral antioxidants in the form of multivitamins and minerals (amino acid chelated)
Study: 19302638
Drug: Low-Dose Infusion
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose Infusion (LDI)
Study: 19302638
Drug: High-Dose Epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose Epidural (Control)
Study: 11216925
Drug: Protease inhibitor-resistant
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor-resistant isolates
Study: 11216925
Drug: Protease inhibitor-sensitive
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor-sensitive isolates
Study: 7861712
Drug: Intermittent calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent calcitriol therapy (oral or intraperitoneal doses) for 12 months
Study: 7861712
Drug: Intermittent calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent calcitriol therapy
Study: 181692
Drug: Caffeine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (1,000 mg daily)
Study: 181692
Drug: Bromocriptine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (40 mg daily)
Study: 31297965
Drug: bexagliflozin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: bexagliflozin (20 mg)
Study: 28550977
Drug: Ezetimibe (10mg/day)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (10mg/day) and Simvastatin (40mg/day) combination therapy
Study: 24517252
Drug: Danoprevir/r 200/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir/r 200/100 mg plus P/R for 24 weeks (Arm A)
Study: 24517252
Drug: Danoprevir/r 100/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir/r 100/100 mg plus P/R for 24 weeks (Arm B)
Study: 24517252
Drug: Danoprevir/r 50/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir/r 50/100 mg plus P/R for 24 weeks (Arm C)
Study: 24517252
Drug: Danoprevir/r 100/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir/r 100/100 mg plus P/R for 12 or 24 weeks (Arm D)
Study: 20889211
Drug: Low-dose peginterferon-α2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose peginterferon-α2a 90 μg/week
Study: 12616178
Drug: Behavioral graded
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral graded activity and problem-solving therapy (GAPS)
Study: 8694309
Drug: 10 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg crystalloid volume
Study: 8694309
Drug: 20 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL/kg crystalloid volume
Study: 8694309
Drug: 30 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL/kg crystalloid volume
Study: 3926848
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with intraaortic balloon pumping and intravenous nitroglycerin for 4 to 5 days
Study: 3926848
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with intraaortic balloon pumping and intravenous nitroglycerin
Study: 28066111
Drug: Low-cost brand
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-cost brand (LCB) amlodipine 5 mg once daily for 6 weeks
Study: 28066111
Drug: Innovator brand
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovator brand (IB) amlodipine 5 mg once daily for 6 weeks
Study: 21510459
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone at a dose of 4 microg/Kg/day
Study: 18951261
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol Diskus 100/50 mcg BID (FSC)
Study: 18951261
Drug: Salmeterol (SAL)
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salmeterol (SAL) 50 mcg BID
Study: 7884423
Drug: Complex therapies
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex therapies evaluated in IRS‐III
Study: 7181476
Drug: Ceforanide (two-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceforanide (two-dose regimen)
Study: 7181476
Drug: Cephalothin (six-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin (six-dose regimen)
Study: 30665464
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (ASA)
Study: 23171536
Drug: cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: cognitive-behavioral therapy (CBT)
Study: 19903773
Drug: Classrooms cleaned
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classrooms cleaned daily with a quaternary ammonium wipe
Study: 19903773
Drug: Control classrooms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control classrooms (not cleaned daily)
Study: 9807603
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 16 ml/kg plus intravenous ephedrine boluses (0.1 mg/kg)
Study: 9807603
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 8 ml/kg plus intramuscular depot ephedrine (0.5 mg/kg)
Study: 9807603
Drug: Haemaccel 8
Normalized name: Haemaccel
DrugBank: Polygeline (DB15879)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemaccel 8 ml/kg plus metaraminol infusion
Study: 2566248
Drug: Clobazam 40
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clobazam 40 mg
Study: 263938
Drug: Dextroamphetamine sulfate
Normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine sulfate 5 mg/70 kg
Study: 263938
Drug: Dextroamphetamine sulfate
Normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine sulfate 10 mg/70 kg
Study: 263938
Drug: Dextroamphetamine sulfate
Normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine sulfate 15 mg/70 kg
Study: 263938
Drug: Dextroamphetamine sulfate
Normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine sulfate 0 mg/70 kg (placebo)
Study: 28352657
Drug: Erlotinib (EGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (EGFR inhibitor)
Study: 28352657
Drug: Dasatinib (Src
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (Src inhibitor)
Study: 28352657
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of erlotinib and dasatinib
Study: 26475403
Drug: 200 ng/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ng/mL cutoff
Study: 26475403
Drug: 500 ng/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ng/mL cutoff
Study: 25098502
Drug: Daily non‐smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily non‐smoking related text messages (control condition)
Study: 10971315
Drug: ORAL +
Normalized name: Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORAL + C
Study: 3775141
Drug: Stress management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress management program for treatment of hypertension (10 weeks duration)
Study: 19104769
Drug: Salsalate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (3 g/day, n = 28)
Study: 17001068
Drug: Bortezomib 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.3 mg/m² administered on days 1, 4, 8, and 11 of a 21-day cycle, for up to 17 cycles.
Study: 14557435
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg twice daily for 3 months, then 1000 mg twice daily for 3 months)
Study: 14557435
Drug: Ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl estradiol (35 micro g)‐cyproterone acetate (2 mg) oral contraceptive pills
Study: 10389531
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg aspirin 1 dd
Study: 8965185
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (Group 1, n = 10)
Study: 8965185
Drug: Placebo bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bolus infusions (Group 2, n = 8)
Study: 6407812
Drug: i.v. verapamil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. verapamil, 5‐10 mg/h for two days
Study: 31478125
Drug: High monocyte
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High monocyte count (HMC) group (monocytes ≥ 0.53 × 10^9/L)
Study: 31478125
Drug: Low monocyte
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low monocyte count (LMC) group (monocytes < 0.53 × 10^9/L)
Study: 24530146
Drug: Self-administered microneedle
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered microneedle patches
Study: 24530146
Drug: Microneedle patches
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedle patches (snap device)
Study: 24530146
Drug: Placebo microneedle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo microneedle patches
Study: 12011795
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (5000 lux from 6-8 a.m.) and imipramine 150 mg/day
Study: 12011795
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (5000 lux from 6-8 a.m.) and imipramine-like placebo
Study: 12011795
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red light (500 lux from 6-8 a.m.) and imipramine 150 mg/day
Study: 30121697
Drug: Bromocriptine 2.5
Normalized name: bromocriptine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 2.5 mg for 1 week (n=10)
Study: 30121697
Drug: Bromocriptine 5
Normalized name: bromocriptine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 5 mg for 2 weeks followed by 2.5 mg for 6 weeks (n=14)
Study: 21767413
Drug: Individualized therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized therapy recommended by clinicians
Study: 1581948
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine integrated with EPI
Study: 28701365
Drug: McKenzie Method
Approvals — FDA: no, EMA: no, PMDA: no
Description: McKenzie Method of Mechanical Diagnosis and Therapy (MDT)
Study: 20842406
Drug: Free base
Normalized name: K201 free base
DrugBank: K201 free base (DB02929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free base tablet formulation (180 mg)
Study: 20842406
Drug: Bisphosphate salt
Normalized name: glucose 1,6-bisphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphate salt capsule formulation (240 mg; 183 mg free base equivalent)
Study: 20842406
Drug: Bisphosphate salt
Normalized name: glucose 1,6-bisphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphate salt capsule formulation (200 mg) administered 3 times a week
Study: 20836725
Drug: PF-592379 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-592379 (200 mg oral dose)
Study: 1964728
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of beta-carotene daily for four weeks
Study: 1964728
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of beta-carotene daily for four weeks
Study: 26516
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg mequitazine daily for 14 days
Study: 26516
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg brompheniramine daily for 14 days